NewLink Genetics Corporation, a Ames, Iowa-based biopharmaceutical company applying innovative approaches to create new therapeutic agents for patients with cancer and infectious diseases, has closed a $30m Series C financing.
The funds will be used to accelerate the clinical development of its therapeutic cancer products.
In an official statement, Dr. Charles Link, Chairman and Chief Executive Officer of the company, explained that “the proceeds of this financing will be used both to expand our cGMP manufacturing capacity and to aggressively move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies”.
These funds bring the total cash raised by New Link Genetics in 2009 just under $20m.
FinSMEs
05/11/2009